Law-medicine interfacing: Patenting of human genes and mutations

Recent Patents on DNA and Gene Sequences

Volumn 5, Issue 2, 2011, Pages 81-85

  Fialho, Arsenio M ^a   Chakrabarty, Ananda M ^b  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

BRCA1 BRCA2 genes; Breast cancer; Drug efficacy; Gene patents; Genetic predisposition; Genetic testing; Human genome; Patent validity; Pharmacogenetics; Protein drugs

Indexed keywords

ACYLTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; AZURIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CLOPIDOGREL; CODEINE; CYTOCHROME P450 1A1; CYTOCHROME P450 2D6; FLUOXETINE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE M3; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; LAZ; TRASTUZUMAB; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; BREAST CANCER; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE PATENT; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC SCREENING; HUMAN; LAW; LAW SUIT; NONHUMAN; OVARY CANCER; PATENT; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

BREAST NEOPLASMS; FEMALE; GENE REARRANGEMENT; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; HUMANS; LEGISLATION, MEDICAL; MUTATION; PATENTS AS TOPIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79959971559     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221511796392015     Document Type: Article

References (31)

1. Eisenberg RS. How can you patent genes? Am J Bioeth 2002; 2: 3-11.
2. Caulfield T, Cook-Deegan RM, Kieff FS, Walsh JP. Evidence and anecdotes: an analysis of human gene patenting controversies. Nat Biotechnol 2006; 24: 1091-4.
3. Chakrabarty AM. In: Kieff FS, Ed. Perspectives on properties of the human genome project. Elsevier Academic Press, San Diego, CA, 2003: pp. 3-11.
4. Doll JJ. The patenting of DNA. Science 1998; 280: 689-90.
5. CREATE Act Examination Guidelines, United States Patent and Trademark Office 1337 CNOG 859, December 30, 2008.
6. Shattuck-Eidens DM, Simard J, Durocher F, Emi M, Nakamura Y. Linked breast and ovarian cancer susceptibility gene. US5693473, 1997.
7. Shattuck-Eidens DM, Simard J, Durocher F, Emi M, Nakamura Y. Linked breast and ovarian cancer susceptibility gene. US5709999, 1998.
8. Skolnick MH, Goldgar DE, Miki Y, et al. 17q-linked breast and ovarian cancer susceptibility gene. US5710001, 1998.
9. Skolnick MH, Goldgar DE, Miki Y, et al. 17q-linked breast and ovarian cancer susceptibility gene. US5747282, 1998.
10. Skolnick MH, Goldgar DE, Miki Y, et al. 17q-linked breast and ovarian cancer susceptibility gene. US5753441, 1998.
11. Tavtigian SV, Kamb A, Simard J, Couch F, Rommens JM, Weber BL. Chromosome 13-linked breast cancer susceptibility gene. US5837492, 1998.
12. Tavtigian SV, Kamb A, Simard J, Couch F, Rommens JM, Weber BL. Chromosome 13-linked breast cancer susceptibility gene. US6033857, 2000.
13. Fialho AM, Chakrabarty AM. In: Fialho AM, Chakrabarty AM, Eds. Emerging cancer therapy: microbial approaches and biotechnological tools. John Wiley & Sons, Hoboken, N.J., 2010: pp. 405-19.
14. Couzin-Frankel J. Chasing a disease to the vanishing point. Science 2010; 328: 298-300.
15. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328: 228-31.
16. Sawyers CL, Gorre ME, Shah NP, Nicoll J. Mutations in the BCRABL tyrosine kinase associated with resistance to STI-571. US0055687, 2010.
17. Chakrabarty AM. Environmental biotechnology in the postgenomics era. Biotech Adv 2003; 22: 3-8.
18. Hutson S. Pharmacogenetics raises new legal questions. Nat Med 2010; 16: 729.
19. Chakrabarty AM. Bioengineered bugs, drugs and contentious issues in patenting. Bioeng Bugs 2010; 1: 2-8.
20. Fialho AM, Chakrabarty AM. In: Fialho AM, Chakrabarty AM, Eds. Emerging cancer therapy: microbial approaches and biotechnological tools. John Wiley & Sons, Hoboken, N.J., 2010: pp. 181-98.
21. Chakrabarty AM, Das Gupta TK, Punj V, Zaborina O. Cytotoxic factors for modulating cell death. US7084105, 2006.
22. Compositions and methods for treating HIV infection with cupredoxins and cytochrome c. Chakrabarty AM, Das Gupta TK, Yamada T, Chaudhari A, Fialho A, Hong CS. US7301010, 2007.
23. Chakrabarty AM, Das Gupta TK, Yamada T, Chaudhari A, Fialho A, Hong CS. Compositions and methods for treating malaria with cupredoxin and cytochrome. US7338766, 2008.
24. Chakrabarty AM, Das Gupta T, Yamada T, Chaudhari A, Fialho A, Zhu Y. Compositions and methods for treating conditions related to ephrin signaling with cupredoxins. US7381701, 2008.
25. Chakrabarty AM, Das Gupta TK, Punj V, Zaborina O, Hiraoka Y, Yamada T. Cytotoxic factors for modulating cell death. US7491394, 2009.
26. Chakrabarty AM, Das GT, Yamada T, Chaudhari A, Fialho A, Hong CS. Compositions and methods for treating HIV infection with cupredoxin and cytochrome c. US7511117, 2009.
27. Mehta RR, Taylor BN, Yamada T, Beattie CW, Das GTK, Chakrabarty AM. Compositions and methods to control angiogenesis with cupredoxins. US7556810, 2009.
28. Das GTK, Chakrabarty AM. Compositions and methods to prevent cancer with cupredoxins US7618939, 2009.
29. Chakrabarty AM, Das GT, Yamada T, Fialho A. Cupredoxin derived transport agents and methods of use thereof. US7691383, 2010.
30. Chakrabarty AM, Das GT, Yamada T, Chaudhari A, Fialho A, Hong CS. Compositions and methods for treating malaria with cupredoxin and cytochrome. US7740857, 2010.
31. Eisenstein M. IPSCs: one cell to rule them all? Nat Methods 2010; 7: 81-4.